Johann V. F.
- Country
- Germany
- Department
- Universitäres Cancer Research Center Hamburg-UCCH
Research Overview
- Phase 2 Evaluation of Neoadjuvant Gemcitabine, Cisplatin, Durvalumab, and Tremelimumab in Intrahepatic Cholangiocarcinoma
- Evaluation of Sequential Versus Up-Front Administration of Durvalumab, Tremelimumab, and Bevacizumab in Non-Resectable Hepatocellular Carcinoma
- Efficacy of Gemcitabine Hydrochloride and Cisplatin Versus Standard Care in Post-Resection Cholangiocarcinoma and Muscle-Invasive Gallbladder Carcinoma
Data & Insights
Has run more than one trial at 32 of 83 partner sites.
Specializations
Hepatology and biliary disease
Clinical research activity is centered in hepatology, with a strong focus on chronic and advanced liver disease, including primary sclerosing cholangitis, primary biliary cholangitis, autoimmune hepatitis, hepatocellular carcinoma, and hepatic encephalopathy. The portfolio also includes interest in cholestatic and cirrhotic conditions that require specialized liver-directed care.
- Primary sclerosing cholangitis
- Primary biliary cholangitis
- Autoimmune hepatitis
- Hepatocellular carcinoma
- Hepatic encephalopathy
Therapeutic interest extends to medical management of progressive liver injury, cholestatic symptoms, and liver-related cancer care.
Transplant medicine and immune-mediated graft injury
The investigator is involved in kidney transplant and liver transplant research, with attention to antibody-mediated rejection, transplant-associated immune complications, and long-term graft preservation. Related interests include post-transplant kidney dysfunction and immune-driven injury in solid-organ recipients.
- Kidney transplant rejection
- Antibody-mediated rejection
- Solid organ transplantation
- Transplant-associated immune complications
- Graft preservation
Research activity also connects with immunosuppressive strategies used to protect transplanted organs and limit inflammatory damage.
Hematologic malignancies and cellular therapy
Substantial activity is seen in blood cancers, especially acute myeloid leukemia, acute lymphoblastic leukemia, multiple myeloma, lymphoma, and related myeloid disorders. The therapeutic landscape includes interest in CAR T-cell therapy, stem cell transplantation, and treatment of relapsed or refractory hematologic disease.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Multiple myeloma
- Lymphoma
- CAR T-cell therapy
Interest also extends to transplant-related hematology and immune complications following intensive treatment for malignancy.
Cardiovascular disease and thromboinflammatory disorders
The trial portfolio includes atrial fibrillation, myocardial infarction, heart failure, stroke, and broader atherosclerotic cardiovascular disease. Additional attention is directed toward thrombotic and bleeding disorders that intersect with cardiovascular risk, including venous thromboembolism and anticoagulation-related decision-making.
- Atrial fibrillation
- Heart failure
- Acute myocardial infarction
- Ischemic stroke
- Venous thromboembolism
Therapeutic interest includes strategies aimed at reducing cardiovascular events and preventing thromboembolic complications.
Inflammatory, autoimmune, and rare disease care
Research involvement also covers immune-mediated and rare disorders such as hidradenitis suppurativa, ulcerative colitis, systemic sclerosis, systemic lupus erythematosus, and myasthenia gravis. The portfolio further includes rare metabolic and genetic conditions, reflecting interest in specialized therapies for complex multisystem disease.
- Hidradenitis suppurativa
- Ulcerative colitis
- Systemic sclerosis
- Systemic lupus erythematosus
- Myasthenia gravis
Additional therapeutic interest includes rare metabolic disease, complement-mediated kidney disease, and other chronic inflammatory conditions requiring targeted treatment options.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.